Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   36391   clinical trials with a EudraCT protocol, of which   5995   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2017-002245-29
    Sponsor's Protocol Code Number:BB2121-MM-001
    National Competent Authority:Germany - PEI
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2017-12-04
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedGermany - PEI
    A.2EudraCT number2017-002245-29
    A.3Full title of the trial
    A phase 2, multicenter study to determine the efficacy and safety of bb2121 in subjects with relapsed and refractory multiple myeloma
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study to assess the safety of bb2121 in people who have Myeloma that is not responsive after treatment or who had Myeloma which has returned after a period of treatment.
    A.4.1Sponsor's protocol code numberBB2121-MM-001
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT03361748
    A.5.3WHO Universal Trial Reference Number (UTRN)U1111-1202-5554
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorCelgene Corporation
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportCelgene Corporation
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationCelgene Corporation
    B.5.2Functional name of contact pointClinicalTrialDisclosure
    B.5.3 Address:
    B.5.3.1Street Address9225 Indian Creek Parkway, Suite 900
    B.5.3.2Town/ cityOverland Park, Kansas
    B.5.3.3Post code66210
    B.5.3.4CountryUnited States
    B.5.4Telephone number+1 888260 1599
    B.5.5Fax number+1 913266 0394
    B.5.6E-mailClinicalTrialDisclosure@celgene.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/17/1863
    D.3 Description of the IMP
    D.3.1Product nameAutologous T lymphocyte-enriched population of cells transduced with a lentiviral vector
    D.3.2Product code bb2121
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNAutologous CD3+ T Cells Expressing BCMA Chimeric Antigen Receptor
    D.3.9.2Current sponsor codebb2121
    D.3.10 Strength
    D.3.10.1Concentration unit Other
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Yes
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product Yes
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Yes
    D.3.11.3.5.1CAT classification and reference numberEMA/758319/2016
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) Yes
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms Yes
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Relapsed and Refractory Multiple Myeloma
    E.1.1.1Medical condition in easily understood language
    Cancer of the bone marrow that recurs or is resistant to treatment
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level LLT
    E.1.2Classification code 10067095
    E.1.2Term Multiple myeloma progression
    E.1.2System Organ Class 100000004864
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 16.1
    E.1.2Level HLT
    E.1.2Classification code 10028229
    E.1.2Term Multiple myelomas
    E.1.2System Organ Class 100000004851
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the efficacy, defined as overall response rate (ORR), of bb2121 in subjects with relapsed and refractory multiple myeloma (RRMM)
    E.2.2Secondary objectives of the trial
    - Assess additional efficacy outcomes, including complete response (CR) rate, time to response (TTR), duration of response (DOR), progression-free survival (PFS), time to progression (TTP) and overall survival (OS)
    - Assess the safety of bb2121 in subjects with RRMM
    - Characterize the expansion of chimeric antigen receptor (CAR)+ Tcells in the peripheral blood (cellular kinetics- pharmacokinetics [PK])
    - Evaluate the development of an anti-CAR antibody response
    - Evaluate the proportion of subjects who attain minimal residual disease (MRD) negative status by next generation sequencing (NGS)
    - Describe changes in health-related quality of life (HRQol) using the European Organization for Research and Treatment of Cancer- Quality of life C30 questionnaire (EORTC-QLQ-C30), the European Quality of LIfe-5 Dimensions health state classifier to 5 Levels (EQ-5D-5L) and the European Quality of Life Multiple Myeloma Module(EORTC-QLQ-MY20)
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Eligibility is determined prior to leukapheresis. Subjects must satisfy the following criteria to be enrolled in the study:
    1. Subject is ≥ 18 years of age at the time of signing the informed consent form (ICF).
    2. Documented diagnosis of multiple myeloma
    - Must have received at least 3 prior MM treatment regimens. Note: induction with or without hematopoietic stem cell transplant and with or without maintenance therapy is considered a single regimen.
    - Must have undergone at least 2 consecutive cycles of treatment for each regimen, unless PD was the best response to the regimen.
    - Must have received a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody.
    - Must be refractory to the last treatment regimen. Refractory is defined as documented progressive disease during or within 60 days (measured from the last dose) of completing treatment with the last anti-myeloma drug regimen before study entry.
    3. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
    4. Subjects must have measurable disease, including at least one of the criteria below:
    - Serum M-protein greater or equal to 1.0 g/dL
    - Urine M-protein greater or equal to 200 mg/24 h
    - Serum free light chain (FLC) assay: involved FLC level greater or equal to 10 mg/dL (100 mg/L) provided serum FLC ratio is abnormal
    - Bone marrow plasma cells > 30% of total bone marrow cells
    5. Recovery to Grade 1 or baseline of any non-hematologic toxicities due to prior treatments, excluding alopecia and Grade 2 neuropathy.
    6. Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.
    7. Subject is willing and able to adhere to the study visit schedule and other protocol requirements within this protocol as well as agrees to continued follow-up for up to 15 years as mandated by the regulatory guidelines for gene therapy trials.
    8. Females of childbearing potential (FCBP (see note 1 below)) must:
    - Have a negative pregnancy test as verified by the Investigator, one negative serum beta human chorionic gonadotropin [β-hCG] pregnancy test result at screening, prior to LD chemotherapy. This applies even if the subject practices true abstinence* from heterosexual contact.
    - Either commit to true abstinence* from heterosexual contact or agree to use, and be able to comply with, effective measures of contraception without interruption, from screening through at least 1 year following lymphodepleting chemotherapy. Contraception methods must include 1 highly effective and 1 additional effective (barrier) method of contraception from screening until at least 1 year following lymphodepleting chemotherapy. There are insufficient exposure data to provide any recommendation concerning the duration of contraception following treatment with bb2121. Any decision regarding contraception after bb2121 infusion should be discussed with the treating physician.
    - Agree to abstain from breastfeeding during study participation . There is insufficient exposure data to provide any recommendation concerning the total duration of abstaining from breastfeeding following treatment with bb2121. Any decision regarding breastfeeding after bb2121 infusion should be discussed with the treating physician.
    - Refrain from tissue donation including egg donation or any other tissue/blood/organ donations for at least 1 year following lymphodepleting chemotherapy. There are insufficient exposure data to provide any recommendation concerning the duration of refraining from tissue donation following treatment with bb2121. Any decision regarding tissue donation after bb2121 infusion should be discussed with the treating physician.

    Male subjects must:
    - Practice true abstinence* or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential for at least 1-year post lymphodepleting chemotherapy, even if he has undergone a successful vasectomy. Subjects will be followed from screening until at least 1 year following lymphodepleting chemotherapy. There are insufficient exposure data to provide any recommendation concerning the duration of contraception following treatment with bb2121. Any decision regarding contraception after bb2121 infusion should be discussed with the treating physician.
    - Refrain from tissue donation including sperm or any other tissue/blood/organ donation for at least 1 year following lymphodepleting chemotherapy. There are insufficient exposure data to provide any recommendation concerning the duration of refraining from tissue donation following treatment with bb2121. Any decision regarding tissue donation after bb2121 infusion should be discussed with the treating physician.

    Note: Highly effective methods are defined in the protocol. True abstinence is defined in the protocol. A female of childbearing potential is defined in the protocol.

    E.4Principal exclusion criteria
    The presence of any of the following will exclude a subject from enrollment:
    1. Subjects with known central nervous system involvement with myeloma.
    2. History or presence of clinically relevant central nervous system (CNS) pathology such as epilepsy, seizure, paresis, aphasia, stroke, subarachnoid hemorrhage or other CNS bleed, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis. (Note: this criterion does not apply to subjects undergoing retreatment unless Grade 4 neurotoxicity was observed following prior treatment with bb2121).
    3. Subjects with active or history of plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or clinically significant amyloidosis.
    4. Subjects with solitary plasmacytomas or non-secretory myeloma without other evidence of measurable disease.
    5. Inadequate hepatic function defined by AST and/or ALT > 2.5 × upper limit of normal (ULN) and total bilirubin > 1.5 × ULN (unless due to Gilbert’s syndrome and direct bilirubin is ≤ 1.5 x ULN).
    6. Inadequate renal function defined by CrCl ≤ 45 ml/min using Cockcroft-Gault equation.
    7. International ratio (INR) or partial thromboplastin time (PTT) > 1.5 × ULN, or history of Grade ≥2 hemorrhage within 30 days, or subject requires ongoing treatment with chronic, therapeutic dosing of anti-coagulants (eg, warfarin, low molecular weight heparin, or Factor Xa inhibitors).
    8. Inadequate bone marrow function defined by absolute neutrophil count (ANC) < 1000 cells/mm3 in the absence of growth factor support (filgrastim within 7 days or peg-filgrastim within 14 days of screening) and platelet count < 50,000 mm3 in the absence of transfusion support (platelet transfusion within 7 days of screening).
    9. Echocardiogram or MUGA with left ventricular ejection fraction < 45%.
    10. Inadequate pulmonary function as defined as oxygen saturation (Sa02) < 92 % on room air.
    11. Ongoing treatment with chronic immunosuppressants (eg, cyclosporine or systemic steroids at any dose). Intermittent topical, inhaled or intranasal corticosteroids are allowed.
    12. Previous history of an allogeneic hematopoietic stem cell transplantation or treatment with any gene therapy-based therapeutic for cancer or investigational cellular therapy for cancer or BCMA targeted therapy.
    13. Evidence of human immunodeficiency virus (HIV) infection.
    14. Seropositive for and with evidence of active viral infection with hepatitis B virus (HBV)
    - Subjects who are hepatitis B surface antigen (HBsAg) negative and HBV viral DNA negative are eligible
    - Subjects who had hepatitis B but have received an antiviral treatment and show non-detectable viral DNA for 6 months are eligible
    - Subjects who are seropositive because of hepatitis B virus vaccine are eligible
    - Subjects with known HBV infection should have undetectable HBV viral load and be maintained on anti-viral therapy to prevent HBV reactivation.
    15. Seropositive for and with active viral infection with hepatitis C virus (HCV)
    - Subjects who had hepatitis C but have received an antiviral treatment and show no detectable HCV viral RNA for 6 months are eligible.
    16. Subjects with a history of class III or IV congestive heart failure (CHF) or severe non-ischemic cardiomyopathy, unstable or poorly controlled angina, myocardial infarction, or ventricular arrhythmia within the previous 6 months prior to starting study treatment.
    17. Subjects with second malignancies in addition to myeloma if the second malignancy has required therapy in the last 3 years or is not in complete remission; exceptions to this criterion include successfully treated non-metastatic basal cell or squamous cell skin carcinoma, carcinoma in situ of the cervix, carcinoma in situ of the breast, or incidental histologic finding of prostate cancer (T1a or T1b using the TNM [tumor nodes, metastasis clinical staging system]) or prostate cancer that is curative.
    18. Subjects who are pregnant, or who intend to become pregnant during participation in the study.
    19. Subject with known hypersensitivity to any component of bb2121 product, cyclophosphamide, fludarabine or tocilizumab.
    20. Subject has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.
    21. Subject has any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study. This includes systemic fungal, bacterial, viral, or other infection that is uncontrolled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antimicrobial treatment) or requiring IV antimicrobials for management.
    22. Subject has any condition that confounds the ability to interpret data from the study.
    E.5 End points
    E.5.1Primary end point(s)
    Overall Response Rate (ORR):
    Percentage of subjects who achieved partial response (PR) or better according to IMWG Uniform Response Criteria for Multiple Myeloma (Kumar, 2016) as assessed by an independent response committee (IRC)
    E.5.1.1Timepoint(s) of evaluation of this end point
    When all bb2121 treated subjects have completed a
    minimum of 10 months of post bb2121 infusion follow up. An updated analysis will be performed following a minimum of 24 months of post bb2121 infusion follow up and additional ad hoc analyses will be performed as appropriate.
    E.5.2Secondary end point(s)
    *Key Secondary
    - Complete Response (CR) Rate:
    Percentage of subjects who achieved CR or sCR according to IMWG Uniform Response Criteria for Multiple Myeloma (Kumar, 2016) as assessed by an IRC

    *Other Secondary
    - Time to Response: Time from first bb2121 infusion to first documentation of response of PR or better
    - Duration of Response (DOR): Time from first documentation of response of PR or better to first documentation of disease progression or death from any cause, whichever occurs first
    - Progression-free Survival (PFS): Time from first bb2121 infusion to first documentation of progressive disease (PD), or death due to any cause, whichever occurs first
    - Time to Progression (TTP): Time from first bb2121 infusion to first documentation of PD
    - Overall Survival (OS): Time from first bb2121 infusion to time of death due to any cause
    - Safety: Type, frequency, and severity of adverse events (AEs), adverse events of special interest (AESI), serious adverse events (SAEs), cytokine release syndrome, neurotoxicity, infection and laboratory abnormalities
    - PK: Maximum transgene level (Cmax), time to peak transgene level (Tmax), area under the curve of transgene level (AUC), including maximum expansion and duration of persistence of bb2121 CD3+ cells
    - Immunogenicity: Evaluate the development of an anti-CAR antibody response
    - Minimal Residual Disease (MRD): Evaluate subjects for MRD status using next generation sequencing (NGS)
    - Health Related Quality of Life (HRQoL): Subject-reported outcomes as measured by EORTC-QLQC30, EQ-5D-5L and EORTC-QLQ-MY20.
    E.5.2.1Timepoint(s) of evaluation of this end point
    When all bb2121 treated subjects have completed sufficient follow-up, e.g. a minimum of 6 months post bb2121 infusion follow up. An updated analysis will be performed at 24 months after the last subject has received bb2121 infusion, or at other timepoints as needed.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic Yes
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned3
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA9
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Belgium
    Canada
    France
    Germany
    Italy
    Spain
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The End of Trial is defined as either the date of the last visit of the last
    subject to complete the post-treatment follow-up, or the date of receipt
    of the last data point from the last subject that is required for primary,
    secondary and/or exploratory analysis, as pre-specified in the protocol,
    whichever is the later date.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years4
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years4
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 82
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 58
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state15
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 57
    F.4.2.2In the whole clinical trial 140
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Because this protocol involves gene transfer, long-term follow-up for lentiviral vector safety will be followed under a separate LTFU protocol, for up to 15 years after bb2121 infusion. Subjects will be followed on the current protocol for myeloma response and disease status for a minimum of 24-months post bb2121 infusion or until documented PD, whichever is longer (or minimum of 6 months for subjects retreated with a second bb2121 infusion). Further details are provided in the protocol.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2018-05-22
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2018-10-02
    P. End of Trial
    P.End of Trial StatusOngoing
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2020 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA